Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Shareholding

12th Sep 2008 07:00

RNS Number : 2849D
ABCAM Plc
12 September 2008
 



For immediate release

12 September 2008

ABCAM PLC

("Abcam" or "the Company")

Shareholding

Cambridge UK, 11 September 2008: Abcam plc announces that in accordance with the FSA's Disclosure and Transparency Rules, the Company has been notified that, as at 10 September 2008, Standard Life Investments Limited has a direct interest in voting rights over 426,077 ordinary shares of 1p each in the Company amounting to approximately 1.215% of the issued share capital of the Company and an indirect interest in voting rights over 3,773,621 ordinary shares of 1p each in the Company amounting to approximately 10.761% of the issued share capital of the Company; amounting to a direct and indirect interest of approximately 11.976% of the issued share capital of the Company.

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

Numis Securities

+ 44 (0) 20 7776 1500

Michael Meade / Nick Westlake (Nominated adviser)

James Black (Corporate broking) 

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Mary-Jane Johnson

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in CambridgeUK, with a US office located in CambridgeMassachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of approximately 44,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs approximately 184 staff in its three operating companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUARBRWURKAAR

Related Shares:

ABC.L
FTSE 100 Latest
Value8,809.74
Change53.53